Neuronetics Schedules Q1 2026 Earnings Release and Conference Call
Event summary
- Neuronetics to release Q1 2026 financial results on May 5, 2026, before market open.
- Conference call scheduled for 8:30 AM ET on the same day to discuss results.
- Company operates Greenbrook TMS treatment centers offering NeuroStar Advanced Therapy and SPRAVATO®.
- NeuroStar Advanced Therapy System cleared by FDA for multiple neurohealth indications.
The big picture
Neuronetics' Q1 2026 earnings release comes at a time when the mental health sector is seeing increased demand for non-drug treatments. The company's focus on TMS therapy and its expansion through Greenbrook TMS treatment centers positions it as a key player in the neurohealth space. Investors will be watching for signs of sustained revenue growth and operational efficiency as the company navigates a competitive landscape.
What we're watching
- Revenue Growth
- Whether Neuronetics can sustain growth in its TMS therapy business amid increasing competition.
- Regulatory Dynamics
- The pace at which FDA approvals for new neurohealth indications will expand the company's market.
- Operational Efficiency
- How effectively Greenbrook TMS treatment centers integrate with Neuronetics' core business strategy.